These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32683996)

  • 41. Supersaturating drug delivery systems: The potential of co-amorphous drug formulations.
    Laitinen R; Löbmann K; Grohganz H; Priemel P; Strachan CJ; Rades T
    Int J Pharm; 2017 Oct; 532(1):1-12. PubMed ID: 28870764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Supercritical fluid particle design for poorly water-soluble drugs (review).
    Sun Y
    Curr Pharm Des; 2014; 20(3):349-68. PubMed ID: 23651403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanocrystals Technology for Improving Bioavailability of Poorly Soluble Drugs: A Mini-Review.
    Zhou Y; Du J; Wang L; Wang Y
    J Nanosci Nanotechnol; 2017 Jan; 17(1):18-28. PubMed ID: 29616786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Physical stability and dissolution behaviors of amorphous pharmaceutical solids: Role of surface and interface effects.
    Shi Q; Moinuddin SM; Wang Y; Ahsan F; Li F
    Int J Pharm; 2022 Sep; 625():122098. PubMed ID: 35961416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
    Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
    Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates.
    Alam MA; Ali R; Al-Jenoobi FI; Al-Mohizea AM
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1419-40. PubMed ID: 23043303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Comprehensive Insight on Pharmaceutical Co-crystals for Improvement of Aqueous Solubility.
    Malik J; Khatkar A; Nanda A
    Curr Drug Targets; 2023; 24(2):157-170. PubMed ID: 36380409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization.
    Zou Z; Huang Q; Li X; Liu X; Yin L; Zhao Y; Liang G; Wu W
    Eur J Pharm Sci; 2023 Sep; 188():106526. PubMed ID: 37442486
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs.
    He CX; He ZG; Gao JQ
    Expert Opin Drug Deliv; 2010 Apr; 7(4):445-60. PubMed ID: 20201713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
    van Hoogevest P; Liu X; Fahr A
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1481-500. PubMed ID: 21895540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review.
    Kapoor DU; Singh S; Sharma P; Prajapati BG
    AAPS PharmSciTech; 2023 Dec; 24(8):253. PubMed ID: 38062314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nanocrystalization: An Emerging Technology to Enhance the Bioavailability of Poorly Soluble Drugs.
    Joshi K; Chandra A; Jain K; Talegaonkar S
    Pharm Nanotechnol; 2019; 7(4):259-278. PubMed ID: 30961518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
    Zhang X; Li LC; Mao S
    Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update.
    Jermain SV; Brough C; Williams RO
    Int J Pharm; 2018 Jan; 535(1-2):379-392. PubMed ID: 29128423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy.
    Bohr A; Nascimento TL; Harmankaya N; Weisser JJ; Wang Y; Grohganz H; Rades T; Löbmann K
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30642009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
    Vasconcelos T; Sarmento B; Costa P
    Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The polymorphism of statins and its effect on their physicochemical properties.
    Karaźniewicz-Łada M; Bąba K; Dolatowski F; Dobrowolska A; Rakicka M
    Polim Med; 2018; 48(2):77-82. PubMed ID: 30916495
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clay-based Formulations for Bioavailability Enhancement of Poorly Water-soluble Drugs.
    Tran PHL; Tran TTD
    Curr Drug Metab; 2021; 22(9):726-734. PubMed ID: 34151758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation of Drug Crystallization and Molecular Interactions by Additives in Solid Dispersions for Improving Drug Bioavailability.
    Tran PHL; Duan W; Lee BJ; Tran TTD
    Curr Pharm Des; 2019; 25(18):2099-2107. PubMed ID: 31244413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.